Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in Advanced Pancreatic Cancer
NCT02726854Phase 2Unknown
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Apr 2016
- Primary completion
- Dec 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in pancreatic cancer (PC), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoints: Progression-Free Survival at 8 weeks and Objective Response Rate at 8 weeks. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT02726854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02726854.